Relatively few recurrent point mutations are identified in primary prostate tumors [44]; however, approximately 50% of prostate tumors carry a TMPRSS2-ERG translocation [9], which could be considered a highly tumor-specific molecular biomarker for ctDNA quantification in blood or urine samples. The gene discussed is ERG; the disease is prostate neoplasm.